316 related articles for article (PubMed ID: 30592275)
61. Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial.
Anton RF; Voronin KE; Book SW; Latham PK; Randall PK; Glen WB; Hoffman M; Schacht JP
Alcohol Clin Exp Res; 2020 Oct; 44(10):2084-2096. PubMed ID: 32772383
[TBL] [Abstract][Full Text] [Related]
62. Influence of genetic variants of opioid-related genes on opioid-induced adverse effects in patients with lung cancer: A STROBE-compliant observational study.
Tanaka R; Sato J; Ishikawa H; Sato T; Shino M; Ohde Y; Sato T; Mori K; Notsu A; Ohnami S; Mizuguchi M; Nagashima T; Yamaguchi K
Medicine (Baltimore); 2021 Nov; 100(44):e27565. PubMed ID: 34871222
[TBL] [Abstract][Full Text] [Related]
63. [Genetic variation-- important for the clinical effect of opioids?].
Klepstad P; Dale O; Borchgrevink PC; Kaasa S; Skorpen F
Tidsskr Nor Laegeforen; 2005 Oct; 125(19):2655-8. PubMed ID: 16215614
[TBL] [Abstract][Full Text] [Related]
64. OPRM1 c.118A>G Polymorphism and Duration of Morphine Treatment Associated with Morphine Doses and Quality-of-Life in Palliative Cancer Pain Settings.
Hajj A; Halepian L; Osta NE; Chahine G; Kattan J; Rabbaa Khabbaz L
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28346387
[TBL] [Abstract][Full Text] [Related]
65. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.
Lötsch J; Skarke C; Liefhold J; Geisslinger G
Clin Pharmacokinet; 2004; 43(14):983-1013. PubMed ID: 15530129
[TBL] [Abstract][Full Text] [Related]
66. Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment.
Walter C; Lötsch J
Pain; 2009 Dec; 146(3):270-275. PubMed ID: 19683391
[TBL] [Abstract][Full Text] [Related]
67. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients.
Rakvåg TT; Klepstad P; Baar C; Kvam TM; Dale O; Kaasa S; Krokan HE; Skorpen F
Pain; 2005 Jul; 116(1-2):73-8. PubMed ID: 15927391
[TBL] [Abstract][Full Text] [Related]
68. The impact of OPRM1's genetic polymorphisms on methadone maintenance treatment in opioid addicts: a systematic review.
Oueslati B; Moula O; Ghachem R
Pharmacogenomics; 2018 Jun; 19(8):741-747. PubMed ID: 29785888
[TBL] [Abstract][Full Text] [Related]
69. Pharmacogenomics of oxycodone: a narrative literature review.
Umukoro NN; Aruldhas BW; Rossos R; Pawale D; Renschler JS; Sadhasivam S
Pharmacogenomics; 2021 Apr; 22(5):275-290. PubMed ID: 33728947
[TBL] [Abstract][Full Text] [Related]
70. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy.
Chou WY; Wang CH; Liu PH; Liu CC; Tseng CC; Jawan B
Anesthesiology; 2006 Aug; 105(2):334-7. PubMed ID: 16871067
[TBL] [Abstract][Full Text] [Related]
71. The role of hydromorphone and OPRM1 in postoperative pain relief with hydrocodone.
Boswell MV; Stauble ME; Loyd GE; Langman L; Ramey-Hartung B; Baumgartner RN; Tucker WW; Jortani SA
Pain Physician; 2013; 16(3):E227-35. PubMed ID: 23703421
[TBL] [Abstract][Full Text] [Related]
72. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.
Crews KR; Gaedigk A; Dunnenberger HM; Leeder JS; Klein TE; Caudle KE; Haidar CE; Shen DD; Callaghan JT; Sadhasivam S; Prows CA; Kharasch ED; Skaar TC;
Clin Pharmacol Ther; 2014 Apr; 95(4):376-82. PubMed ID: 24458010
[TBL] [Abstract][Full Text] [Related]
73. Combined analysis of circulating β-endorphin with gene polymorphisms in OPRM1, CACNAD2 and ABCB1 reveals correlation with pain, opioid sensitivity and opioid-related side effects.
Rhodin A; Grönbladh A; Ginya H; Nilsson KW; Rosenblad A; Zhou Q; Enlund M; Hallberg M; Gordh T; Nyberg F
Mol Brain; 2013 Feb; 6():8. PubMed ID: 23402298
[TBL] [Abstract][Full Text] [Related]
74. Correlation between gene polymorphism and opioid efficacy in patients with gastric or intestinal cancer.
Pu J; Wang N; Huang ZK; He XY; Yuan HB
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(21):9393-9410. PubMed ID: 31773688
[TBL] [Abstract][Full Text] [Related]
75. Genotypic screening of the main opiate-related polymorphisms in a cohort of 139 sickle cell disease patients.
Joly P; Gagnieu MC; Bardel C; Francina A; Pondarre C; Martin C
Am J Hematol; 2012 May; 87(5):534-6. PubMed ID: 22430884
[TBL] [Abstract][Full Text] [Related]
76. The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy.
Reynolds KK; Ramey-Hartung B; Jortani SA
Clin Lab Med; 2008 Dec; 28(4):581-98. PubMed ID: 19059064
[TBL] [Abstract][Full Text] [Related]
77. Challenges in interpreting joined allelic combinations of OPRM1 and COMT genes.
Landau R; Ortner C; Carvalho B
Anesth Analg; 2011 Aug; 113(2):432. PubMed ID: 21788333
[No Abstract] [Full Text] [Related]
78. Exploratory study on association of single-nucleotide polymorphisms with hydromorphone analgesia in ED.
Xia S; Persaud S; Birnbaum A
Am J Emerg Med; 2015 Mar; 33(3):444-7. PubMed ID: 25576257
[TBL] [Abstract][Full Text] [Related]
79. A functional polymorphism in the ATP-Binding Cassette B1 transporter predicts pharmacologic response to combination of nortriptyline and morphine in neuropathic pain patients.
Benavides R; Vsevolozhskaya O; Cattaneo S; Zaykin D; Brenton A; Parisien M; Verma V; Khoury S; Gilron I; Diatchenko L
Pain; 2020 Mar; 161(3):619-629. PubMed ID: 31738228
[TBL] [Abstract][Full Text] [Related]
80. [Effect of opioid-related gene polymorphisms on patients with high-dose opioid-tolerant cancer pain].
Xie GL; Zhang W; Li ZG; Guo DP; Liu C
Zhonghua Yi Xue Za Zhi; 2019 Dec; 99(47):3720-3724. PubMed ID: 31874497
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
